APA (7th ed.) Citation

G, H., DA, C., L, T., R, B., D, B., A, H., . . . GJ, O. (2025). Midostaurin added to 10-day decitabine, for patients unfit for intensive chemotherapy with AML and higher risk MDS, irrespective of FLT3 mutational status, does not improve outcome. Annals of hematology, 104(1), 361. https://doi.org/10.1007/s00277-024-06033-y

Chicago Style (17th ed.) Citation

G, Huls, et al. "Midostaurin Added to 10-day Decitabine, for Patients Unfit for Intensive Chemotherapy with AML and Higher Risk MDS, Irrespective of FLT3 Mutational Status, Does Not Improve Outcome." Annals of Hematology 104, no. 1 (2025): 361. https://doi.org/10.1007/s00277-024-06033-y.

MLA (9th ed.) Citation

G, Huls, et al. "Midostaurin Added to 10-day Decitabine, for Patients Unfit for Intensive Chemotherapy with AML and Higher Risk MDS, Irrespective of FLT3 Mutational Status, Does Not Improve Outcome." Annals of Hematology, vol. 104, no. 1, 2025, p. 361, https://doi.org/10.1007/s00277-024-06033-y.